SPDR S&P Biotech ETF

XBI

Market cap $6.1B

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the SPDR S&P Biotech ETF (XBI), a passively managed exchange traded fund launched on January 31, 2006.

Too many questionable start-ups went public during the pandemic, when the sector was hot. Now, after over four years of pain, the weak have failed, rates are falling, and M&A looks to be on the upswing.

Rod Wong, RTW Investments CIO & Managing Director, joins CNBC's 'Money Movers' to discuss J&J's reported interest in buying Protagonist Therapeutics, whether he expects more consolidation in the sector, and much more.

Joe Terranova, senior managing director at Virtus Investment Partners, joins CNBC's "Halftime Report" to explain why he's buying XBI again. The committee share their health care strategy.

The health care sector up 6.5% in one week. The Investment Committee debate how to trade the space.

AI's growing role in cancer research, and a new federal push for pediatric oncology, are powering gains in key healthcare ETFs.

President Donald Trump delivered the pharmaceutical industry another blow this week, threatening 100% tariffs on some companies.

The Investment Committee's top stock picks are in—here's what they're watching now.

Launched on 01/31/2006, the SPDR S&P Biotech ETF (XBI) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market.

The Federal Reserve's inflation battle appears to be ending, and investors who position themselves correctly could capture significant gains. Producer prices unexpectedly dropped in August, while the U.S. government revised past employment figures downward by a staggering 911,000 jobs.